Multiple System Atrophy (MSA)

Multiple system atrophy (MSA) is a sporadic, progressive, adult-onset, degenerative disease that presents with a combination of parkinsonism, cerebellar and autonomic dysfunction. The diagnosis of this disease is challenging and its delayed diagnosis is common. MSA is a synucleinopathy, characterised by α-synuclein-positive oligodendrocytic glial cytoplasmic inclusions, also known as Papp-Lantos bodies. Striatonigral degeneration and olivopontocerebellar atrophy are self-descriptive neuropathological observations used to classify the main pathological subtypes of MSA. Clinically, the condition is categorised into MSA-parkinsonian variant (MSA-P) and MSA-cerebellar variant (MSA-C), based on the predominant motor phenotype. MSA-P is associated with striatonigral degeneration pathology and MSA-C with olivopontocerebellar atrophy, although most patients have mixed clinical and pathological features.

In clinical trials Singer et. Al. In a phase I/II study sought to explore the intrathecal administration of mesenchymal stem cells (MSCs) as a therapeutic approach to multiple system atrophy (MSA). Twenty-four patients received treatment. There were no attributable serious adverse events, and injections were generally well-tolerated. At the highest dose tier, 3 of 4 patients developed low back/posterior leg pain, associated with thickening/enhancement of lumbar nerve roots. Although there were no associated neurologic deficits. A total of 6 from 12 patients in the medium dose tier developed similar, but milder and transient discomfort. the observed clinical effect was associated with a marked rise in neurotrophic factors in the spinal fluid documented to be present for at least 4 weeks following MSC administration. This effect was also dose-dependent and convincingly seen only in the medium- and high-dose tiers, though concentration of most neurotrophic factors was just at or below detection threshold for the baseline samples. there is increasingly convincing evidence based on preclinical studies and clinical trials that MSCs have an intriguing potential of modifying the disease course of MSA.

Multiple system atrophy (MSA)

Citations and Scientific References

Our medical unit is highly esteemed for partnering globally with fellow researchers on scientific studies and contributing to respected scientific journals.

View References